Anwerina

Anwerina is a Berlin-based biotechnology company dedicated to advancing circular RNA (circRNA) technology for the treatment of aggressive cancers, with a primary focus on glioblastoma multiforme. As a spin-off from the University of Zurich and University Hospital Zurich, the company leverages a proprietary platform to design and produce circRNA molecules that offer superior stability and prolonged protein expression compared to conventional linear mRNA. Anwerina's lead programs involve circRNA-based immunotherapies designed to modulate the tumor microenvironment and stimulate a robust anti-tumor immune response. The company is currently in the pre-clinical stage, supported by investments from venture capital firms such as High-Tech Gründerfonds and IBB Ventures.